13.06  2.11 (19.27%)		01-09 16:00
Open: 12.4755 High: 13.14 Volume: 5,995,596		Pre. Close: 10.95 Low: 12.2 Market Cap: 1,282(M)

Short term
Mid term
Targets	6-month :	15.34	1-year :	17.92
Resists	First :	13.14	Second :	15.34
Pivot price	11.28
Supports	First :	10.85	Second :	9.43
MAs	MA(5) :	11.44	MA(20) :	11.1
	MA(100) :	10.24	MA(250) :	12.63
MACD	MACD :	0.5	Signal :	0.5
%K %D	K(14,3) :	70	D(3) :	62.2
RSI	RSI(14): 69.7
52-week	High :	18.89	Low :	6.65

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SPRY ] has closed above the upper band by 15.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	13.16 - 13.23	13.23 - 13.3
Low:	12.01 - 12.11	12.11 - 12.19
Close:	12.92 - 13.06	13.06 - 13.19

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Fri, 09 Jan 2026
What's Going On With ARS Pharmaceuticals Stock Friday? - ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga

Fri, 09 Jan 2026
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Yahoo Finance

Fri, 09 Jan 2026
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Approval Expands Neffy Allergy Market Reach - Sahm

Thu, 08 Jan 2026
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey

Tue, 30 Dec 2025
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - simplywall.st

Mon, 10 Nov 2025
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	99 (M)
Held by Insiders	1.0541e+008 (%)
Held by Institutions	16.8 (%)
Shares Short	20,140 (K)
Shares Short P.Month	0 (K)

EPS	-8.981e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-56.1 %
Operating Margin	-163.7 %
Return on Assets (ttm)	-19.3 %
Return on Equity (ttm)	-46 %
Qtrly Rev. Growth	1 %
Gross Profit (p.s.)	589.5
Sales Per Share	1.78462e+008
EBITDA (p.s.)	1.43588e+008
Qtrly Earnings Growth	-0.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-85 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	7.01

Dividend	0
Forward Dividend	2.159e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.